The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs).
These alterations are associated with increased MET activity and preclinical sensitivity to …

UCSC Xena is a visual exploration resource for both public and private omics data,
supported through the web-based Xena Browser and multiple turn-key Xena Hubs. This …

Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades
as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the …

Abstract The Cancer Genome Atlas profiled 279 head and neck squamous cell carcinomas
(HNSCCs) to provide a comprehensive landscape of somatic genomic alterations. Here we …

This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report
molecular profiling of 230 resected lung adenocarcinomas using messenger RNA …

Alternative splicing changes are frequently observed in cancer and are starting to be
recognized as important signatures for tumor progression and therapy. However, their …

Recent studies have highlighted that splicing patterns are frequently altered in cancer and
that mutations in genes encoding spliceosomal proteins, as well as mutations affecting the …